Clinical Trials
224
21 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1929
Active, not recruiting
1
0.5%
Completed
161
71.9%
Enrolling By Invitation
1
0.5%
Not yet recruiting
19
8.5%
Recruiting
40
17.9%
Unknown
2
0.9%
No approval data available
- Pin1 inhibitors, including H-77 and four newly developed compounds, successfully stopped HSV-1 replication at concentrations as low as 1 μM in laboratory tests. - The inhibitors work through a unique mechanism by stabilizing nuclear membrane structure, physically trapping viral particles within the cell nucleus and preventing their escape. - Researchers aim to develop Pin1 inhibitors as host-directed therapeutics that could be less prone to drug resistance compared to traditional antivirals. - The findings represent a potential breakthrough for treating HSV-1, which affects 50-90% of people worldwide and can be life-threatening in immunocompromised patients.
- Researchers at Hiroshima University discovered that fermented stevia extract demonstrates significantly greater cytotoxicity against pancreatic cancer cells compared to non-fermented stevia extract. - The fermentation process with Lactobacillus plantarum SN13T creates chlorogenic acid methyl ester (CAME), which selectively kills cancer cells while sparing healthy kidney cells. - Laboratory tests showed fermented stevia extract blocks cancer cells at specific life cycle phases and triggers apoptosis, offering potential for targeted cancer therapy development. - The findings represent early-stage research requiring animal and human studies before clinical applications can be considered.
- A community-based pneumococcal vaccination support program in Sera Town, Japan, providing PPSV23 vaccines to residents 65 years and older reduced pneumonia-related mortality by 25% according to a real-world study published in the Journal of Epidemiology. - The program, which ran from 2010-2015 and achieved 43% participation among eligible residents, reversed the previously increasing trend in pneumonia mortality in the community. - Post-vaccination pneumonia incidence decreased to 0.04 per 1000 population compared with 0.23 per 1000 population before the program implementation. - The findings demonstrate the significant community-wide benefits of targeted pneumococcal vaccination programs for high-risk elderly populations in preventing severe disease outcomes.
